Genetic Technologies Limited (GENE) is a big mover this session with its shares spiking nearly 11% following a 13G filing in which Capital Ventures International discloses a 9.7% passive stake in the company.
Genetic Technologies stock began trading this morning at $4.66 to currently trade $0.36 higher from the prior days close of $4.40. On an intraday basis it has gotten as low as $4.65 and as high as $5.25.
On valuation measures, the company’s current year and next year EPS growth estimates stand at 26.80% and 14.00%, respectively. The name has a trailing-12 price/sales ratio of 8.58. EPS for the same period registers at ($1.65).
Genetic shares have advanced 6.02% in the last 4 weeks and 125.64% in the past three months. Over the past 5 trading sessions the stock has lost 29.60%. Shares of Genetic Technologies Limited are up 125.64% this year.
The Fitzroy, Australia-based provider of genetic testing services, which is currently valued at $26.93 million, has a high Wall Street price target of $12.50. GENE is down 47% year-over-year, compared with an 12.21% gain in the S&P 500.